• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGEN alert in real time by email
    SC 13G/A 1 sch13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 1)*
     

     
    Oragenics, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.001 per share
     
     
    (Title of Class of Securities)
     

     
    684023500
     
     
    (CUSIP Number)
     

     
    September 30, 2024
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    0
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.0%
     
    12
    Type of Reporting Person (See Instructions)
    PN
     




    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    0
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.0%
     
    12
    Type of Reporting Person (See Instructions)
    OO
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    0
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.0%
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     




    Item 1.
    (a)
    Name of Issuer
     
     
    Oragenics, Inc.
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    1990 Main Street
    Suite 750
    Sarasota, FL 34236

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •    Lind Global Fund II LP, a Delaware limited partnership;
    •    Lind Global Partners II LLC, a Delaware limited liability company; and
    •    Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
    Common Stock, par value $0.001 per share
    (e)
    CUSIP Number
     
     
    684023500
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.  Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
    Item 6.  Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits     Exhibit

    99.1                  Joint Filing Agreement by and among the Reporting Persons.


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    November 14, 2024
     
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton



    Get the next $OGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OGEN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OGEN
    SEC Filings

    See more
    • SEC Form S-1 filed by Oragenics Inc.

      S-1 - ORAGENICS INC (0001174940) (Filer)

      6/23/25 6:18:20 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - ORAGENICS INC (0001174940) (Filer)

      5/28/25 7:00:25 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ORAGENICS INC (0001174940) (Filer)

      5/20/25 5:10:16 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Odyssey Health, Inc. sold $30,407 worth of Common Stock - OGEN (7,044 units at $4.32), closing all direct ownership in the company (SEC Form 4)

      4 - ORAGENICS INC (0001174940) (Issuer)

      6/18/25 5:10:06 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Odyssey Health, Inc. sold $43,600 worth of Common Stock - OGEN (10,000 units at $4.36), decreasing direct ownership by 59% to 7,044 units (SEC Form 4)

      4 - ORAGENICS INC (0001174940) (Issuer)

      6/16/25 6:01:26 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Odyssey Health, Inc. claimed ownership of 249,623 units of Series F Preferred Stock and claimed ownership of 17,044 shares (SEC Form 3)

      3 - ORAGENICS INC (0001174940) (Issuer)

      6/16/25 5:54:50 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

      SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15–18, 2025, in Philadelphia, Pennsylvania. These back-to-back events represent key opportunities for Oragenics to highlight its lead candidate, ONP-002, an intranasal neurosteroid in development for the treatment of concussion (mild

      6/10/25 8:30:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split

      SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the "Board") on May 27, 2025 approved a One-for-Thirty (1-for-30) reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on June 3, 2025. As a result of the Reverse Stock Split, every 30 pre-split shares of common stock out

      5/28/25 7:00:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

      SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase II clinical trial evaluating ONP-002, the Company's proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion. This approval marks a significant milestone in expanding Oragenics' clinical development efforts internationally. With this clearance, Oragenics can initiate clinical trials in Australia and could begin patient enrollment as e

      5/13/25 8:30:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman Sachs initiated coverage on Oragenics with a new price target

      Goldman Sachs initiated coverage of Oragenics with a rating of Neutral and set a new price target of $52.00

      6/3/21 6:23:39 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health

      SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly's appointment to the Medical Board reflects his leadership in brain injury resear

      2/24/25 8:30:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

      SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

      1/21/25 8:15:00 AM ET
      $MEDS
      $OGEN
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Oragenics Appoints William "Frank" Peacock MD as Chief Clinical Officer

      SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (mTBI), commonly known as concussion, in the field and emergency departments. ONP-002 is a new chemical entity (NCE) designed to target the brain through deliver

      5/22/24 8:00:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

      SC 13G/A - ORAGENICS INC (0001174940) (Subject)

      11/14/24 7:29:57 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

      SC 13G/A - ORAGENICS INC (0001174940) (Subject)

      11/14/24 3:59:00 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Oragenics Inc.

      SC 13G - ORAGENICS INC (0001174940) (Subject)

      9/11/24 7:45:36 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Financials

    Live finance-specific insights

    See more
    • Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

      TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Offic

      2/12/21 8:00:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care